Catalyst Wire Dossier Catalyst Wire Dossier

Zabadinostat

· ImmunityBio, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Zabadinostat, covering 2026-03-23 to 2026-03-23. Get the full timeline:

Most recent: Clinical Trial Update: Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer [Phase 1]

See pricing